Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Short term Debt (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Short term Debt for 16 consecutive years, with $750000.0 as the latest value for Q4 2025.

  • Quarterly Short term Debt fell 77.22% to $750000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $750000.0 through Dec 2025, down 77.22% year-over-year, with the annual reading at $750000.0 for FY2025, 77.22% down from the prior year.
  • Short term Debt for Q4 2025 was $750000.0 at Plus Therapeutics, down from $3.3 million in the prior quarter.
  • The five-year high for Short term Debt was $6.8 million in Q3 2021, with the low at $750000.0 in Q4 2025.
  • Average Short term Debt over 5 years is $3.7 million, with a median of $3.4 million recorded in 2024.
  • The sharpest move saw Short term Debt surged 214.49% in 2023, then tumbled 77.22% in 2025.
  • Over 5 years, Short term Debt stood at $6.8 million in 2021, then crashed by 76.18% to $1.6 million in 2022, then soared by 147.26% to $4.0 million in 2023, then dropped by 17.2% to $3.3 million in 2024, then crashed by 77.22% to $750000.0 in 2025.
  • According to Business Quant data, Short term Debt over the past three periods came in at $750000.0, $3.3 million, and $3.3 million for Q4 2025, Q4 2024, and Q3 2024 respectively.